Pharma Industry

While expanded traceability aims to curb counterfeit medicines, industry says predictive manufacturing could help reduce NSQ drugs

The antitrust watchdog rejected its Director General's findings, ruling there was no evidence of anti-competitive agreements involving stockist appointments or new drug launches

Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i

Indian drugmakers are reducing reliance on US generics, turning to specialty medicines, biosimilars and emerging markets to drive sustainable growth

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

For decades, India excelled at making affordable generic medicines. But creating a brand-new drug from scratch remained a rare achievement. Now, Wockhardt has made history with Zaynich

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Clears way for higher rates for Cisplatin and Carboplatin amid supply crunch

After a near fourfold expansion driven by generic semaglutide launches, India's GLP-1 market is showing signs of moderation as patient onboarding growth slows

Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138

India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday reported an 86 per cent dip in consolidated profit after tax at Rs 221.3 crore in the fourth quarter ended March 31, 2026 hit by lower generics sales in North America. The company had posted a profit after tax of Rs 1,586.7 crore in the corresponding quarter previous fiscal year, Dr Reddy's Laboratories Ltd said in a regulatory filing. Consolidated total revenue from operations in the fourth quarter stood at Rs 7,546.4 crore as against Rs 8,528.4 crore in the same period a year ago, it added. Revenue from generic drugs in North America in the quarter was down 51 per cent at Rs 1,756.2 crore as compared to Rs 3,558.6 crore in the year-ago period. On the other hand generics revenue in India grew 20 per cent at Rs 1,566.3 crore as compared to Rs 1,304.7 crore in the corresponding period a year ago, the company said. Similarly, generics revenue in Europe grew by 14 per cent to Rs 1,452 crore from Rs 1,275 crore in the year ago period.

The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Govt urges pharma firms to cut import reliance, boost domestic production and diversify exports as data shows rising foreign value addition and heavy dependence on China and the US

The deal creates Apothecon Group, a specialty pharma company focused on regulated markets in the US, Europe and India, with plans to expand its pipeline, footprint and acquisitions

Indian pharma market's growth was led more by price increases that an uptick in consumption

Pharma firm acquires office units in Parinee I building as Mumbai office market sees rising absorption, lower vacancies, and steady growth in rentals